ACB
HAE icon

Aristotle Capital Boston’s Haemonetics HAE Stock Holding History

Aristotle Capital Boston’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7M Sell
289,624
-56,762
-16% -$3.65M 1.46% 14
2026
Q1 		$19.5M Sell
346,386
-23,922
-6% -$1.56M 1.21% 25
2025
Q4 		$29.7M Sell
370,308
-33,854
-8% -$2.27M 1.63% 11
2025
Q3 		$19.7M Buy
404,162
+41,215
+11% +$2.55M 1.02% 35
2025
Q2 		$27.1M Sell
362,947
-28,914
-7% -$1.91M 1.38% 22
2025
Q1 		$24.9M Buy
391,861
+11,244
+3% +$765K 1.24% 25
2024
Q4 		$29.7M Buy
380,617
+22,011
+6% +$1.77M 1.1% 33
2024
Q3 		$28.8M Buy
358,606
+55,232
+18% +$4.46M 0.95% 45
2024
Q2 		$25.1M Sell
303,374
-18,152
-6% -$1.6M 0.84% 50
2024
Q1 		$27.4M Buy
321,526
+16,246
+5% +$1.27M 0.83% 49
2023
Q4 		$26.1M Sell
305,280
-6,386
-2% -$552K 0.8% 53
2023
Q3 		$27.9M Sell
311,666
-1,330
-0.4% -$119K 0.9% 46
2023
Q2 		$26.6M Buy
312,996
+7,212
+2% +$610K 0.8% 48
2023
Q1 		$25.3M Buy
305,784
+7,634
+3% +$618K 0.78% 52
2022
Q4 		$23.4M Sell
298,150
-7,721
-3% -$621K 0.74% 58
2022
Q3 		$22.6M Sell
305,871
-26,140
-8% -$1.88M 0.77% 51
2022
Q2 		$21.6M Buy
332,011
+21,396
+7% +$1.27M 0.65% 65
2022
Q1 		$19.6M Sell
310,615
-6,697
-2% -$364K 0.5% 88
2021
Q4 		$16.8M Sell
317,312
-5,688
-2% -$347K 0.39% 104
2021
Q3 		$22.8M Buy
323,000
+73,322
+29% +$4.63M 0.53% 84
2021
Q2 		$16.6M Sell
249,678
-14,050
-5% -$994K 0.38% 100
2021
Q1 		$29.3M Buy
263,728
+32,258
+14% +$3.99M 0.65% 70
2020
Q4 		$27.5M Sell
231,470
-12,839
-5% -$1.38M 0.65% 65
2020
Q3 		$21.3M Buy
+244,309
New +$21.4M 0.62% 66

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aristotle Capital Boston's HAE Position: Q2 2026 in Review

Aristotle Capital Boston reduced its Haemonetics (HAE) stake by 16% in Q2 2026, selling an estimated $3.65M and leaving 289,624 shares worth $21.7M. The position accounts for 1.46% of the portfolio, ranked #14.

Aristotle Capital Boston first reported a position in HAE in Q3 2020 and has held it in 24 quarters since. The position peaked at $29.7M in Q4 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Aristotle Capital Boston held 289,624 shares of Haemonetics worth $21.7M as of Q2 2026.
  • Aristotle Capital Boston sold 56,762 Haemonetics shares in Q2 2026, an estimated $3.65M.
  • Haemonetics made up 1.46% of Aristotle Capital Boston's portfolio in Q2 2026, its #14 holding.
  • Aristotle Capital Boston first reported a position in Haemonetics in Q3 2020 and has held it in 24 quarters since.
  • Aristotle Capital Boston's Haemonetics position peaked at $29.7M in Q4 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Aristotle Capital Boston's 13F filing for Q2 2026, filed 14 Aug 2026.